https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52820 Tue 14 Nov 2023 11:54:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38317 via esterification. Among them, compounds 2e (IC₅₀ =105 nM) and 3b (IC₅₀ =114 nM) displayed excellent ACE inhibitory activity in vitro, and exhibited non-toxic to H9c2 cells. The interactions between ACE and compounds were predicted by molecular docking respectively. In verapamil-induced zebrafish HF model, the activity assay showed that these two derivatives could improve cardiovascular physiological indexes including heart beats, venous congestion, heart dilation, cardiac output, ejection fraction and fractional shortening in a dose-dependent manner. A UPLC-QTOF-MS-based serum metabolomics approach was applied to explore the latent mechanism. A total of 25 differentiated metabolites and 8 perturbed metabolic pathways were identified. These results indicated that pyxinol fatty acid ester derivatives 2e and 3b might be considered as potent drug candidates against heart failure and deserved further research and development.]]> Mon 29 Jan 2024 18:52:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55404 Mon 27 May 2024 12:04:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38667 Mon 13 Dec 2021 16:13:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36757 Fri 03 Jul 2020 11:18:42 AEST ]]>